, Volume 46, Issue 3, pp 526–531 | Cite as

Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas

  • Ju-Yeon Kim
  • Taejin Park
  • Sang-Ho Jeong
  • Chi-Young Jeong
  • Young-Tae Ju
  • Young-Joon Lee
  • Soon-Chan Hong
  • Woo-Song Ha
  • Sang-Kyung Choi
  • Eun Jung JungEmail author
Original Article


Inflammation is associated with several tumor development and progression. However, these associations are not clear in well-differentiated thyroid carcinomas. We assessed whether NLR is a useful prognostic marker in patients with papillary thyroid carcinomas (PTC). The medical records of all patients who underwent thyroid surgery at a single institution between March 2005 and September 2012 were retrospectively evaluated; as a control group, patients who underwent routine health examinations in 2012 were also evaluated. Differences in mean NLR among patient groups were assessed, and clinical characteristics according to NLR quartile were evaluated in patients with PTC. The association between NLR and disease-free survival (DFS) in PTC patients was determined. NLR was significantly higher in the groups with than without thyroid nodules, but did not differ significantly in patients with benign and malignant thyroid nodules. Mean NLR was significantly higher in patients with solid or mixed thyroid than in patients with cystic nodules (1.75 ± 0.92 vs. 1.65 ± 0.74, p = 0.004). Patient follow-up ranged from 6 to 99 months. At 5-year follow-up, 11 patients had disease-specific events. We found that 5-year DFS rate was significantly worse in stages III and IV patients with NLR ≥1.5 than NLR <1.5 (94.1 vs. 99.3 %, p = 0.013). The univariate Cox hazard proportional hazard model for DFS revealed that higher NLR was independently correlated with poorer prognosis (hazard ratio 8.76; 95 % confidence interval 1.09–70.27, p = 0.041). Higher NLR may be a negative prognostic marker for DFS in patients with PTC, especially those with stages III and IV.


Neutrophil to lymphocyte ratio Thyroid Cancer Prognosis 



The authors have declared no conflicts of interest.

Supplementary material

12020_2013_89_MOESM1_ESM.doc (55 kb)
Supplementary material 1 (DOC 55 kb)


  1. 1.
    L.M. Coussens, Z. Werb, Inflammation and cancer. Nature 420(6917), 860–867 (2002). doi: 10.1038/nature01322 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    T.L. Whiteside, The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904–5912 (2008). doi: 10.1038/onc.2008.271 PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    H. Nozawa, C. Chiu, D. Hanahan, Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103(33), 12493–12498 (2006). doi: 10.1073/pnas.0601807103 PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    D.C. McMillan, The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat. Rev. 39(5), 534–540 (2013). doi: 10.1016/j.ctrv.2012.08.003 PubMedCrossRefGoogle Scholar
  5. 5.
    G.J. Guthrie, K.A. Charles, C.S. Roxburgh, P.G. Horgan, D.C. McMillan, S.J. Clarke, The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. (2013). doi: 10.1016/j.critrevonc.2013.03.010 PubMedGoogle Scholar
  6. 6.
    H. Yu, X. Huang, X. Liu, H. Jin, G. Zhang, Q. Zhang, J. Yu, Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 44(1), 172–181 (2013). doi: 10.1007/s12020-012-9853-2 PubMedCrossRefGoogle Scholar
  7. 7.
    M.H. Rho, D.W. Kim, H.P. Hong, Y.M. Park, M.J. Kwon, S.J. Jung, Y.W. Kim, T. Kang, Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results. Endocrine 42(3), 647–653 (2012). doi: 10.1007/s12020-012-9695-y PubMedCrossRefGoogle Scholar
  8. 8.
    S.D. Larson, L.N. Jackson, T.S. Riall, T. Uchida, R.P. Thomas, S. Qiu, B.M. Evers, Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J. Am. Coll. Surg. 204(5), 764–773 (2007). doi: 10.1016/j.jamcollsurg.2006.12.037. discussion 773–765PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    D.P. Bradly, V. Reddy, R.A. Prinz, P. Gattuso, Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery 146(6), 1099–1104 (2009). doi: 10.1016/j.surg.2009.09.025 PubMedCrossRefGoogle Scholar
  10. 10.
    Y. Lun, X. Wu, Q. Xia, Y. Han, X. Zhang, Z. Liu, F. Wang, Z. Duan, S. Xin, J. Zhang, Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol. Head Neck Surg. 148(3), 396–402 (2013). doi: 10.1177/0194599812472426 PubMedCrossRefGoogle Scholar
  11. 11.
    J.S. Jeong, H.K. Kim, C.R. Lee, S. Park, J.H. Park, S.W. Kang, J.J. Jeong, K.H. Nam, W.Y. Chung, C.S. Park, Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J. Korean Med. Sci. 27(8), 883–889 (2012). doi: 10.3346/jkms.2012.27.8.883 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    P. Del Rio, S. Cataldo, L. Sommaruga, L. Concione, M.F. Arcuri, M. Sianesi, The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer? Minerva Endocrinol. 33(1), 1–5 (2008)PubMedGoogle Scholar
  13. 13.
    E.Y. Kim, W.G. Kim, W.B. Kim, T.Y. Kim, J.M. Kim, J.S. Ryu, S.J. Hong, G. Gong, Y.K. Shong, Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 71(4), 581–586 (2009). doi: 10.1111/j.1365-2265.2009.03537.x CrossRefGoogle Scholar
  14. 14.
    C.L. Liu, J.J. Lee, T.P. Liu, Y.C. Chang, Y.C. Hsu, S.P. Cheng, Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J. Surg. Oncol. 107(5), 493–497 (2013). doi: 10.1002/jso.23270 PubMedCrossRefGoogle Scholar
  15. 15.
    B.D. Edge SB, C.C. Compton, A.G. Frits, F.L. Greene, A. Trotti, AJCC cancer staging manual, 7th edn. (Springer, New York, 2010)Google Scholar
  16. 16.
    H. Ubukata, G. Motohashi, T. Tabuchi, H. Nagata, S. Konishi, T. Tabuchi, Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J. Surg. Oncol. 102(7), 742–747 (2010). doi: 10.1002/jso.21725 PubMedCrossRefGoogle Scholar
  17. 17.
    M. Aizawa, N. Gotohda, S. Takahashi, M. Konishi, T. Kinoshita, Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J. Surg. 35(12), 2717–2722 (2011). doi: 10.1007/s00268-011-1269-2 PubMedCrossRefGoogle Scholar
  18. 18.
    M.R. Jung, Y.K. Park, O. Jeong, J.W. Seon, S.Y. Ryu, D.Y. Kim, Y.J. Kim, Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J. Surg. Oncol. 104(5), 504–510 (2011). doi: 10.1002/jso.21986 PubMedCrossRefGoogle Scholar
  19. 19.
    R.Z. Sharaiha, K.J. Halazun, F. Mirza, J.L. Port, P.C. Lee, A.I. Neugut, N.K. Altorki, J.A. Abrams, Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann. Surg. Oncol. 18(12), 3362–3369 (2011). doi: 10.1245/s10434-011-1754-8 PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    M. Di Bari, F. Salvi, A.T. Roberts, D. Balzi, B. Lorenzetti, V. Morichi, L. Rossi, F. Lattanzio, N. Marchionni, Prognostic stratification of elderly patients in the emergency department: a comparison between the “Identification of Seniors at Risk” and the “Silver Code”. J. Gerontol. A 67(5), 544–550 (2012). doi: 10.1093/gerona/glr209 CrossRefGoogle Scholar
  21. 21.
    Y. Mohri, K. Tanaka, M. Ohi, T. Yokoe, C. Miki, M. Kusunoki, Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J. Surg. 34(2), 285–290 (2010). doi: 10.1007/s00268-009-0302-1 PubMedCrossRefGoogle Scholar
  22. 22.
    H. Shimada, N. Takiguchi, O. Kainuma, H. Soda, A. Ikeda, A. Cho, A. Miyazaki, H. Gunji, H. Yamamoto, M. Nagata, High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13(3), 170–176 (2010). doi: 10.1007/s10120-010-0554-3 PubMedCrossRefGoogle Scholar
  23. 23.
    I. Bhatti, O. Peacock, G. Lloyd, M. Larvin, R.I. Hall, Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am. J. Surg. 200(2), 197–203 (2010). doi: 10.1016/j.amjsurg.2009.08.041 PubMedCrossRefGoogle Scholar
  24. 24.
    D.S. Wang, H.Y. Luo, M.Z. Qiu, Z.Q. Wang, D.S. Zhang, F.H. Wang, Y.H. Li, R.H. Xu, Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med. Oncol. 29(5), 3092–3100 (2012). doi: 10.1007/s12032-012-0226-8 PubMedCrossRefGoogle Scholar
  25. 25.
    S.R. Walsh, E.J. Cook, F. Goulder, T.A. Justin, N.J. Keeling, Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91(3), 181–184 (2005). doi: 10.1002/jso.20329 PubMedCrossRefGoogle Scholar
  26. 26.
    H.C. Kwon, S.H. Kim, S.Y. Oh, S. Lee, J.H. Lee, H.J. Choi, K.J. Park, M.S. Roh, S.G. Kim, H.J. Kim, J.H. Lee, Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17(3), 216–222 (2012). doi: 10.3109/1354750X.2012.656705 PubMedCrossRefGoogle Scholar
  27. 27.
    T. Motomura, K. Shirabe, Y. Mano, J. Muto, T. Toshima, Y. Umemoto, T. Fukuhara, H. Uchiyama, T. Ikegami, T. Yoshizumi, Y. Soejima, Y. Maehara, Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J. Hepatol. 58(1), 58–64 (2013). doi: 10.1016/j.jhep.2012.08.017 PubMedCrossRefGoogle Scholar
  28. 28.
    M. Tomita, T. Shimizu, T. Ayabe, A. Yonei, T. Onitsuka, Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 31(9), 2995–2998 (2011)PubMedGoogle Scholar
  29. 29.
    T. Gondo, J. Nakashima, Y. Ohno, O. Choichiro, Y. Horiguchi, K. Namiki, K. Yoshioka, M. Ohori, T. Hatano, M. Tachibana, Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79(5), 1085–1091 (2012). doi: 10.1016/j.urology.2011.11.070 PubMedCrossRefGoogle Scholar
  30. 30.
    S. Teramukai, T. Kitano, Y. Kishida, M. Kawahara, K. Kubota, K. Komuta, K. Minato, T. Mio, Y. Fujita, T. Yonei, K. Nakano, M. Tsuboi, K. Shibata, K. Furuse, M. Fukushima, Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur. J. Cancer 45(11), 1950–1958 (2009). doi: 10.1016/j.ejca.2009.01.023 PubMedCrossRefGoogle Scholar
  31. 31.
    O.K. Idowu, Q. Ding, A.F. Taktak, C.R. Chandrasekar, Q. Yin, Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers 17(6), 539–544 (2012). doi: 10.3109/1354750X.2012.699554 PubMedCrossRefGoogle Scholar
  32. 32.
    H. Cho, H.W. Hur, S.W. Kim, S.H. Kim, J.H. Kim, Y.T. Kim, K. Lee, Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol. Immunother. 58(1), 15–23 (2009). doi: 10.1007/s00262-008-0516-3 PubMedCrossRefGoogle Scholar
  33. 33.
    J.-D. Lin, C. Hsueh, T.-C. Chao, Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19(10), 1053–1059 (2009). doi: 10.1089/thy.2009.0133 PubMedCrossRefGoogle Scholar
  34. 34.
    C. Seretis, S. Gourgiotis, G. Gemenetzis, F. Seretis, E. Lagoudianakis, G. Dimitrakopoulos, The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am. J. Surg. 205(6), 691–696 (2013). doi: 10.1016/j.amjsurg.2012.08.006 PubMedCrossRefGoogle Scholar
  35. 35.
    K. Pietras, A. Ostman, Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316(8), 1324–1331 (2010). doi: 10.1016/j.yexcr.2010.02.045 PubMedCrossRefGoogle Scholar
  36. 36.
    C.S. Roxburgh, D.C. McMillan, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6(1), 149–163 (2010). doi: 10.2217/fon.09.136 PubMedCrossRefGoogle Scholar
  37. 37.
    H.T. Petrie, L.W. Klassen, H.D. Kay, Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J. Immunol. 134(1), 230–234 (1985)PubMedGoogle Scholar
  38. 38.
    H.D. Kay, D.L. Smith, Regulation of human lymphocyte-mediated natural killer (NK) cell activity. I. Inhibition in vitro by peripheral blood granulocytes. J. Immunol. 130(1), 475–483 (1983)PubMedGoogle Scholar
  39. 39.
    H.Y. Shau, A. Kim, Suppression of lymphokine-activated killer induction by neutrophils. J. Immunol. 141(12), 4395–4402 (1988)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ju-Yeon Kim
    • 1
  • Taejin Park
    • 1
  • Sang-Ho Jeong
    • 1
  • Chi-Young Jeong
    • 1
  • Young-Tae Ju
    • 1
  • Young-Joon Lee
    • 1
  • Soon-Chan Hong
    • 1
  • Woo-Song Ha
    • 1
  • Sang-Kyung Choi
    • 1
  • Eun Jung Jung
    • 1
    Email author
  1. 1.Department of Surgery, School of MedicineGyeongsang National UniversityJin-juSouth Korea

Personalised recommendations